Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid-Sparing Anti-Emetic Therapy in Chemotherapy
NCT05590923Phase 4Terminated
- Sponsor
- Guthrie
- Start
- Dec 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Guthrie. Primary endpoint: Complete Response at 120 hours. Started Dec 2022; status: terminated.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05590923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590923.